News | Verici Dx

Product rebranding as Tutivia^TM

November 1, 2022

Verici Dx’s post-transplant test, Tuteva, to be rebranded as TutiviaTM Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its post-transplant blood test focused on acute rejection, has been rebranded as TutiviaTM. TutiviaTM (formerly known as Tuteva), is a blood-based RNA signature for a risk score for acute […]

Keep Reading

Half-year report

September 7, 2022

Strong data in validation study for Tuteva™ paving the way for commercial launch

Keep Reading

Positive results for Clarava™ from blinded multi-centre clinical validation study

September 6, 2022

Data validates Clarava’s ability to identify patients likely to experience future kidney transplant rejection

Keep Reading

Result of AGM and voting results

June 28, 2022

Verici DX announces that at the Annual General Meeting

Keep Reading

Distribution of Verici Dx shares by EKF Diagnostics Holdings plc

June 20, 2022

Verici DX notes the announcement made by EKF Diagnostics Holdings PLC

Keep Reading

Investor Update

June 16, 2022

Sara Barrington, CEO, will provide a live presentation relating to positive data from the Tuteva™ clinical validation study via the Investor Meet Company platform

Keep Reading

Outlining positive data from Tuteva™ clinical validation study Test performance better than existing care “by multiple times”

June 15, 2022

Verici Dx announces an interview with Chief Executive, Sara Barrington.

Keep Reading

Further data from Tuteva™ clinical validation study presented

June 14, 2022

Performance in blinded multi-centre trial establishes new industry standard in detection of acute kidney transplant rejection and paves way for US commercial launch in 2022

Keep Reading

Commercial Team Appointments

June 9, 2022

Verici Dx plc announces the senior appointments of Grant Harvey and Dr. Windy Tucci as Business Development Director and Medical Science Liaison Director

Keep Reading

Posting of Annual Report & Accounts and Notice of Annual General Meeting

May 25, 2022

Verici Dx plc confirms that the Annual Report and Accounts and the Notice of the 2022 Annual General Meeting have now been published

Keep Reading

1 2 3 … 6 Next »

Archived News

Verici Dx attended and exhibited at ASN 2022 kidney week national conference

November 2, 2022

Verici Dx attended and exhibited at the ASN kidney week annual conference, from November 3rd to November 6th, 2022, at the Orlando Convention Center, in Orlando FL. Verici Dx, Renalytix, AST, and ASN, have partnered to create the Dr. Barbara T. Murphy endowed lectureship starting at ASN Kidney Week 2022. This lectureship commemorates Dr. Murphy […]

Keep Reading